Atomoxetine and Duloxetine: Evaluation of a Potential Pharmacokinetic Drug-Drug Interaction

1. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391–9.10.1093/ajhp/61.22.239115581262Search in Google Scholar

2. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9.10.1136/adc.2004.059386176527015665154Search in Google Scholar

3. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–90.10.2165/00003088-200544060-0000215910008Search in Google Scholar

4. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002 ;30(3):319–23.10.1124/dmd.30.3.31911854152Search in Google Scholar

5. Yu G, Li G-F, Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26(4):314-26.10.1089/cap.2015.0137487652926859445Search in Google Scholar

6. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281–94.10.2165/11539240-000000000-0000021366359Search in Google Scholar

7. Wernicke JF, Gahimer J, Yalcin I, Wulster-radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf. 2005;4(6):987-93.10.1517/14740338.4.6.98716255658Search in Google Scholar

8. Carter NJ, McCormack PL. Duloxetine: A review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523–41.10.2165/00023210-200923060-0000619480470Search in Google Scholar

9. Sobanski E, Paslakis G, Schredl M et al. Managing ADHD in adults with common comorbidities. In: Surman C, ed. ADHD in adults. A practical guide to evaluation and managament. Current Clinical Psychiatry. Totowa, NJ: Humana Press; 2013. p. 137–54.10.1007/978-1-62703-248-3_8Search in Google Scholar

10. Bond DJ, Hadjipavlou G, Lam RW et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24(1):23–37.Search in Google Scholar

11. Kooij JJS, Bijlenga D, Salerno L et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14–34.10.1016/j.eurpsy.2018.11.00130453134Search in Google Scholar

12. Dodangi N, Habibi N, Astaneh AN. Preliminary investigation on duloxetine efficacy in the treatment of children with attention-deficit hyperactivity disorder. J Compr Pediatr. 2015; 6(4):e27482. doi: 10.17795/compreped-27482.10.17795/compreped-27482Search in Google Scholar

13. Niederhofer H. Duloxetine may improve some symptoms of attention-deficit/hyperactivity disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2): PCC.09l00807. doi: 10.4088/PCC.09l00807pin.10.4088/PCC.09l00807pinOpen DOISearch in Google Scholar

14. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.10.3758/BF03193146Search in Google Scholar

15. Todor I, Popa A, Neag M et al. Evaluation of the potential pharmacokinetic interaction between atomoxetine and fluvoxamine in healthy volunteers. Pharmacology. 2017;99(1-2):84-88.10.1159/000452223Search in Google Scholar

16. Todor I, Popa A, Neag M et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci. 2016;19(2):198–207.10.18433/J3H03RSearch in Google Scholar

17. Todor I, Popa A, Neag M et al. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. Clujul Med. 2015;88(4):513-520.10.15386/cjmed-488Search in Google Scholar

18. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet.2015;387(10024):1240–50.10.1016/S0140-6736(15)00238-XSearch in Google Scholar

19. Biederman J, Petty CR, Evans M, Small J, Faraone S V. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.10.1016/j.psychres.2009.12.010288183720452063Search in Google Scholar

20. Faraone S V, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.10.1017/S003329170500471X16420712Search in Google Scholar

21. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–9.10.1007/s13311-012-0135-8344193622976615Search in Google Scholar

22. Fayyad J, De Graaf R, Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.10.1192/bjp.bp.106.03438917470954Search in Google Scholar

23. Wang B, Yang L-P, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573–643.10.1080/0360253090311872919645588Search in Google Scholar

24. Lin ND, Norman H, Regev A et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015; 15:134. doi: 10.1186/s12876-015-0373-4.10.1186/s12876-015-0373-4460716926467777Open DOISearch in Google Scholar

25. Belle DJ, Ernest CS, Sauer J, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219-27.10.1177/00912700276249130712412820Search in Google Scholar

26. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2015; 12:27-39.10.2147/TCRM.S59270469469326730199Search in Google Scholar

27. Fredriksen M, Halmøy A, Faraone S V, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD : A review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-27.10.1016/j.euroneuro.2012.07.01622917983Search in Google Scholar

28. Hennissen L, Bakker MJ, Banaschewski T et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD : a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199–215.10.1007/s40263-017-0410-7533654628236285Search in Google Scholar

29. Kasi PM, Mounzer R, Gleeson GH. Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep Med. 2011;2011:952584. doi: 10.1155/2011/952584.10.1155/2011/952584313522521765848Search in Google Scholar